Venus Medtech (Hangzhou), Inc. Class H (HK:2500)
:2500
Want to see HK:2500 full AI Analyst Report?
Top Page
Venus Medtech (Hangzhou), Inc. Class H
(2500)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$1.50
▼(-39.02% Downside)
Action:Reiterated
Date:05/04/26
The score is held down primarily by weak financial performance (sharp 2025 revenue decline, persistent losses, and elevated cash burn), reinforced by bearish technicals (below key moving averages and negative MACD). Improved leverage on the balance sheet provides some stability, but valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Structural Heart Focus
Venus Medtech's concentrated focus on transcatheter aortic valve implantation (TAVI) and related interventional cardiovascular devices aligns with durable secular trends: aging populations and migration to less invasive procedures. This specialization supports differentiated R&D, clinical adoption pathways and long-run procedure-driven demand.
Negative Factors
Sharp Revenue Decline
A ~30% revenue drop in 2025 signals weakening commercial traction and scaling difficulty. Reduced procedure volumes or slower hospital adoption directly shrink the addressable near-term revenue base, making investment payback longer and increasing uncertainty around sustainable market share and future revenue recoveries.
Read all positive and negative factors
Positive Factors
Negative Factors
Structural Heart Focus
Venus Medtech's concentrated focus on transcatheter aortic valve implantation (TAVI) and related interventional cardiovascular devices aligns with durable secular trends: aging populations and migration to less invasive procedures. This specialization supports differentiated R&D, clinical adoption pathways and long-run procedure-driven demand.
Read all positive factors
Venus Medtech (Hangzhou), Inc. Class H (2500) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$582.14M
Dividend YieldN/A
Average Volume (3M)2.48M
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth-34.96%
EPS Growth42.74%
CountryHK
Employees691
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.93
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model
Company Description
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product t...
How the Company Makes Money
The company makes money primarily by selling medical devices used in catheter-based cardiovascular procedures. Its key revenue streams are (1) sales of structural heart intervention products—most notably TAVI systems (valves and their delivery sys...
Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
63
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 306.79M | 470.83M | 491.37M | 406.46M | 415.86M |
| Gross Profit | 211.83M | 367.75M | 389.20M | 314.00M | 324.34M |
| EBITDA | -315.42M | -612.96M | -547.84M | -999.37M | -324.03M |
| Net Income | -407.69M | -714.31M | -703.75M | -1.06B | -373.64M |
Balance Sheet | |||||
| Total Assets | 2.52B | 3.25B | 4.41B | 5.28B | 5.11B |
| Cash, Cash Equivalents and Short-Term Investments | 280.52M | 305.70M | 781.64M | 1.88B | 2.96B |
| Total Debt | 216.43M | 369.09M | 826.19M | 899.64M | 70.78M |
| Total Liabilities | 757.14M | 1.04B | 1.49B | 1.65B | 477.61M |
| Stockholders Equity | 1.76B | 2.21B | 2.92B | 3.61B | 4.55B |
Cash Flow | |||||
| Free Cash Flow | -332.12M | -17.82M | -872.93M | -908.23M | -602.08M |
| Operating Cash Flow | -321.35M | 23.74M | -610.02M | -729.46M | -456.92M |
| Investing Cash Flow | 364.06M | -19.90M | -346.86M | -1.07B | -653.04M |
| Financing Cash Flow | -184.05M | -487.34M | -173.99M | 635.14M | 1.39B |
Venus Medtech (Hangzhou), Inc. Class H Technical Analysis
Negative
2.46
Price Trends
1.96
Negative
2.38
Negative
2.80
Negative
Market Momentum
-0.17
Positive
17.17
Positive
3.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2500, the sentiment is Negative. The current price of 2.46 is above the 20-day moving average (MA) of 1.73, above the 50-day MA of 1.96, and below the 200-day MA of 2.80, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 17.17 is Positive, neither overbought nor oversold. The STOCH value of 3.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2500.
Venus Medtech (Hangzhou), Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$7.19B | 27.47 | 4.88% | 0.48% | 35.28% | 146.71% | |
70 Outperform | HK$1.81B | 21.92 | 7.53% | ― | 47.07% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.49B | -6.72 | -11.27% | ― | 16.35% | 9.84% | |
43 Neutral | HK$582.14M | -2.30 | -21.29% | ― | -34.96% | 42.74% | |
43 Neutral | HK$528.74M | -8.27 | -11.54% | ― | -30.60% | 28.61% | |
42 Neutral | HK$2.43B | -1.03 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.40
-1.18
-45.74%
HK:9996
Peijia Medical Ltd.
5.24
-0.51
-8.87%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
21.00
1.51
7.76%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.89
-2.26
-54.46%
HK:2216
Broncus Holding Corp.
0.99
-1.17
-54.17%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
47.00
19.40
70.29%
Venus Medtech (Hangzhou), Inc. Class H Corporate Events
Venus Medtech Executive Director Resigns, Board Signals Smooth Transition
May 15, 2026
Venus Medtech (Hangzhou) Inc., a Hong Kong-listed Chinese medical technology company specializing in cardiovascular devices, is governed by a board that includes executive, non-executive and independent non-executive directors. This structure unde...
Venus Medtech Outlines Board and Committee Roles to Strengthen Governance
May 15, 2026
Venus Medtech (Hangzhou) Inc. has disclosed the current composition of its board of directors, detailing the mix of executive, non-executive, and independent non-executive directors and their respective responsibilities. The announcement clarifies...
Venus Medtech Announces Change of Company Secretary and Authorized Representatives
May 6, 2026
Venus Medtech (Hangzhou) Inc. has announced the resignation of company secretary and authorized representative Mr. Wong Wai Chiu, effective 6 May 2026, with the board noting there is no disagreement or outstanding matter related to his departure t...
Venus Medtech Narrows Losses but Revenue and Margins Slide in 2025
Mar 31, 2026
Venus Medtech reported a sharp year-on-year decline in revenue to RMB306.8 million for 2025, down 34.8%, with gross profit falling 42.4% as commercialization profit margins were squeezed to just 0.5% on a non-IFRS basis. The company nonetheless na...
Venus Medtech Schedules Board Meeting to Approve 2025 Annual Results
Mar 19, 2026
Venus Medtech (Hangzhou) Inc. has scheduled a board meeting for March 31, 2026 to review and approve the audited annual results for the year ended December 31, 2025, and to authorize their publication. The meeting may also address other corporate ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.